Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 combined with paclitaxel with or without bevacizumab for platinum-resistant ovarian cancer
CTR20253674Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in ovarian cancer, sponsored by Leads Biolabs. Started Dec 2025; status: active.
02
Drugs
opamtistomig
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on CTR20253674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253674.